Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?

BACKGROUND: The combination of BRAF and MEK inhibitors represents the standard of care treatment for patients with metastatic BRAF-mutated melanoma, notwithstanding the high frequency of emergent resistance. Moreover, therapeutic options outside clinical trials are scarce when patients have progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Stagno, Anna, Vari, Sabrina, Annovazzi, Alessio, Anelli, Vincenzo, Russillo, Michelangelo, Cognetti, Francesco, Ferraresi, Virginia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202400/
https://www.ncbi.nlm.nih.gov/pubmed/34136385
http://dx.doi.org/10.3389/fonc.2021.645008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202400/
https://www.ncbi.nlm.nih.gov/pubmed/34136385
http://dx.doi.org/10.3389/fonc.2021.645008

Ejemplares similares